Literature DB >> 22180846

Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Sander van der Marel1, Anna Majowicz, Sander van Deventer, Harald Petry, Daniel W Hommes, Valerie Ferreira.   

Abstract

Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders most commonly affecting young adults. Currently available therapies can result in induction and maintenance of remission, but are not curative and have sometimes important side effects. Advances in basic research in IBD have provided new therapeutic opportunities to target the inflammatory process involved. Gene and cell therapy approaches are suitable to prevent inflammation in the gastrointestinal tract and show therefore potential in the treatment of IBD. In this review, we present the current progress in the field of both gene and cell therapy and future prospects in the context of IBD. Regarding gene therapy, we focus on viral vectors and their applications in preclinical models. The focus for cell therapy is on regulatory T lymphocytes and mesenchymal stromal cells, their potential for the treatment of IBD and the progress made in both preclinical models and clinical trials.

Entities:  

Keywords:  Cell therapy; Gene therapy; Immune tolerance; Inflammatory bowel diseases; Mesenchymal stromal cells; Regulatory T lymphocytes; Viral vector

Year:  2011        PMID: 22180846      PMCID: PMC3240904          DOI: 10.4291/wjgp.v2.i6.114

Source DB:  PubMed          Journal:  World J Gastrointest Pathophysiol        ISSN: 2150-5330


  135 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.

Authors:  Matti Waterman; Wei Xu; Joanne M Stempak; Raquel Milgrom; Charles N Bernstein; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2010-12-10       Impact factor: 5.325

Review 3.  The intestinal stem cell.

Authors:  Nick Barker; Marc van de Wetering; Hans Clevers
Journal:  Genes Dev       Date:  2008-07-15       Impact factor: 11.361

4.  Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis.

Authors:  Justine R Smith; Claudie Verwaerde; Fabienne Rolling; Marie-Christine Naud; Anne Delanoye; Brigitte Thillaye-Goldenberg; Florence Apparailly; Yvonne De Kozak
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

5.  Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.

Authors:  Zhe Li; Ingrid Arijs; Gert De Hertogh; Séverine Vermeire; Maja Noman; Dominique Bullens; Lieve Coorevits; Xavier Sagaert; Frans Schuit; Paul Rutgeerts; Jan L Ceuppens; Gert Van Assche
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

6.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

7.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

8.  Suppression of autoimmune diabetes by viral IL-10 gene transfer.

Authors:  Zandong Yang; Meng Chen; Runpei Wu; Lawrence B Fialkow; Jonathan S Bromberg; Marcia McDuffie; Ali Naji; Jerry L Nadler
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

9.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

10.  Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells.

Authors:  Pervinder Sagoo; Niwa Ali; Garima Garg; Frank O Nestle; Robert I Lechler; Giovanna Lombardi
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

View more
  12 in total

1.  Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes.

Authors:  Shan Lu; Viola B Morris; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2015-01-15       Impact factor: 4.939

2.  Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation.

Authors:  Jingjing Zhang; Lili Ding; Baocan Wang; Gaiyan Ren; Aning Sun; Chao Deng; Xiaohui Wei; Sridhar Mani; Zhengtao Wang; Wei Dou
Journal:  J Pharmacol Exp Ther       Date:  2014-12-03       Impact factor: 4.030

3.  Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.

Authors:  Takuro Yoshimoto; Kimie Niimi; Eiki Takahashi
Journal:  Comp Med       Date:  2016-12-01       Impact factor: 0.982

Review 4.  Regulatory T cells in inflammatory bowel diseases and colorectal cancer.

Authors:  Györgyi Műzes; Béla Molnár; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

5.  Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.

Authors:  Sander van der Marel; Anna Majowicz; Karin Kwikkers; Richard van Logtenstein; Anje A te Velde; Anne S De Groot; Sybren L Meijer; Sander J van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

6.  Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Authors:  Wei Dou; Jingjing Zhang; Aning Sun; Eryun Zhang; Lili Ding; Subhajit Mukherjee; Xiaohui Wei; Guixin Chou; Zheng-Tao Wang; Sridhar Mani
Journal:  Br J Nutr       Date:  2013-03-18       Impact factor: 3.718

7.  Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway.

Authors:  Wei Dou; Jingjing Zhang; Hao Li; Sandhya Kortagere; Katherine Sun; Lili Ding; Gaiyan Ren; Zhengtao Wang; Sridhar Mani
Journal:  J Nutr Biochem       Date:  2014-05-09       Impact factor: 6.048

8.  Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling inactivation.

Authors:  Wei Dou; Jingjing Zhang; Gaiyan Ren; Lili Ding; Aning Sun; Chao Deng; Xiaojun Wu; Xiaohui Wei; Sridhar Mani; Zhengtao Wang
Journal:  Int Immunopharmacol       Date:  2014-09-04       Impact factor: 4.932

9.  Serum matrix metalloproteinase 9 (MMP9) as a biochemical marker for wasting marmoset syndrome.

Authors:  Takuro Yoshimoto; Kimie Niimi; Eiki Takahashi
Journal:  J Vet Med Sci       Date:  2016-02-12       Impact factor: 1.267

10.  Murine CD4⁺CD25⁻ cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo.

Authors:  Anna Majowicz; Sander van der Marel; Anje A te Velde; Sybren L Meijer; Harald Petry; Sander J van Deventer; Valerie Ferreira
Journal:  BMC Gastroenterol       Date:  2012-12-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.